• 1
    Burnett AL. Priapism. In: WeinAJ, KavoussiLR, NovickAC, PartinAW, PetersCA, eds. Campbell Walsh urology. 9th edition. Saunders Elsevier: Philadelphia; 2007:83949.
  • 2
    Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID, Members of the Erectile Dysfunction Guideline Update Panel, American Urological Association. American Urological Association guideline on the management of priapism. J Urol 2003;170:131824.
  • 3
    Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W. Priapism. J Sex Med 2004;1:11620.
  • 4
    Beutler E. G6PD deficiency. Blood 1994;84:361336.
  • 5
    Hundsdoefer P, Vetter B, Kulozik AE. Chronic haemolytic anaemia and glucose-6 phosphate dehydrogenase deficiency. Case report and review of the literature. Acta Haematol 2002;108:1025.
  • 6
    Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006;3:107784.
  • 7
    Gaskin RS, Estwick D, Peddi R. G6PD deficiency: Its role in the high prevalence of hypertension and diabetes mellitus. Ethn Dis 2001;11:74954.
  • 8
    Loscalzo J, Voetsch B, Liao R, Leopold J. Genetic determinants of vascular oxidant stress and endothelial dysfunction. Congest Heart Fail 2005;11:739.
  • 9
    Burnett AL, Musicki B, Bivalacqua TJ. Molecular science of priapism. Curr Sex Health Report 2007;4:914.
  • 10
    Burnett AL, Musicki B, Jin L, Bivalacqua TJ. Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. Expert Opin Ther Targets 2006;10:44557.